Clinical trials: Steroid Resistant Acute Graft Versus Host Disease
Acute Graft Versus Host Disease
Intra Arterial (IA) Steroids Infusion for Hepatic Acute Hepatic Graft Versus Host Disease (aGVHD)
Post allogeneic hematopoietic stem cell transplantation (HSCT) patients with steroid resistant acute GVHD localised to the liver will receive 24 hours continuous intra-arterial infusion of methylprednisolone.
- Trial name
- NCT01140984
- Testing
- Methylprednisolone (Intra-arterial continuous infusion of corticosteroids)
- Where
- Israel
- Volunteers
- 2 people
- Sponsor
- Hadassah Medical Organization
COPD, Emphysema or COPD
Steroid Resistance During COPD Exacerbations With Respiratory Failure
Chronic obstructive pulmonary disease (COPD) is a lung disease caused by cigarette smoke that affects millions of people. In the United States, COPD is the 3rd leading cause of death making it one of our most important public…
- Conditions
- COPD, Emphysema or COPD, COPD Exacerbation, COPD Exacerbation Acute
- Trial name
- NCT03680495
- Testing
- Methylprednisolone
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- University of Colorado, Denver
Graft-versus-host-disease
Treatment of Steroid Resistant GVHD by Infusion MSC
For numerous malignant diseases allogeneic hematopoietic stem cell transplantation (HSCT) is the only curative therapy. One of the major complications is the occurrence of acute graft-versus-host-disease (aGVHD).
- Trial name
- MSCforGVHD (NCT00827398)
- Testing
- MSC (hPPL)
- Where
- 2 sites in Netherlands
- Volunteers
- 50 people
- Sponsor
- N.M. Wulffraat
Pediatric Mmune Thrombocytopenic Purpura
Steroid Resistance in Pediatric Immune Thrombocytopenic Purpura
To Predicting steroid resistance on children newly diagnosed with immune thrombocytopenic purpura
- Trial name
- ITP (NCT06601543)
- Volunteers
- 102 people
- Sponsor
- Assiut University
Graft vs Host Disease
Mesenchymal Stem Cells as First Treatment Line for Resistant Acute Graft Versus Host Disease
Steroids are still the first line treatment for established severe acute-graft-versus-host-disease (aGVHD), with a response rate of 30-50%, and there is no established and effective therapy for severe steroid-refractory (aGVHD).
- Trial name
- NCT02770430
- Testing
- mesenchymal stem cells, conventional treatment
- Where
- Brazil
- Volunteers
- 90 people
- Sponsor
- Hospital de Clinicas de Porto Alegre
Steroid Refractory GVHD
Evaluation of EFficacy and SaFEty of Leukotac (Inolimomab) in Pediatric Patients With SR-aGvHD
A Phase 3, Multicenter, open label, study to Evaluate the EFficacy and SaFEty of Leukotac® (inolimomab) in pediatric patients with steroid resistant acute Graft versus Host Disease (SR-aGvHD)
- Trial name
- EiFFEL (NCT04289103)
- Testing
- Inolimomab (Leukotac)
- Volunteers
- 65 people
- Sponsor
- ElsaLys Biotech
Stem Cell Transplant Complications, Acute Graft-Versus-Host Disease
FMT for Steroid Resistant Gut Acute GVHD
The study aims to evaluate the safety and efficacy of fecal microbiota transplantation (FMT) for the treatment of steroid resistant graft-versus-host-disease (GVHD) of the gut.
- Conditions
- Stem Cell Transplant Complications, Acute Graft-Versus-Host Disease, Fecal Microbiota Transplantation
- Trial name
- NCT04285424
- Testing
- Fecal Microbiota Transplantation
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Affiliated Hospital to Academy of Military Medical Sciences
Graft vs Host Disease
Study of BEGEDINA® vs "Conventional Treatment" for Treating Steroid-Resistant Acute GvHD
The objectives of this study are to determine the efficacy and safety of BEGEDINA® in subjects with steroid resistant acute graft versus host disease (GvHD).
- Trial name
- NCT02411084
- Testing
- Begelomab, Conventional Second-line Treatment
- Where
- 27 sites in United States, France and 5 more
- Volunteers
- 36 people
- Sponsor
- Adienne SA